Transcatheter aortic valve replacement: a review of current indications and outcomes.
In patients with symptomatic severe aortic stenosis, surgical aortic valve replacement (SAVR) improves survival, quality of life, and functional status compared with medical therapy. Based on the results of the randomized PARTNER Trial, Transcatheter Aortic Valve Replacement (TAVR) using the Edwards Sapien balloon expandable valve is now available in the United States for patients who are either inoperable due to anatomic concerns or severe medical co-morbidities, or as an alternative in patients considered high risk for SAVR. Fifty-six patients have been treated with TAVR at Rhode Island Hospital from March 2012 through October 2013 with similar outcomes to The PARTNER Trial and several large European registries. Second- generation valves and lower profile delivery systems designed to reduce the incidence of vascular complications, stroke, and perivalvular leak; and extension of TAVR to intermediate risk surgical patients, are under investigation.
Fellow in Cardiology at The Warren Alpert Medical School of Brown University.
William
W
Prabhu
Director of the Cardiac Catheterization Laboratory at The Miriam Hospital, Associate Professor of Medicine (Clinical) in the Department of Medicine at The Warren Alpert Medical School of Brown University, affiliated with the Cardiovascular Institute, Providence, RI.
Paul C
PC
Gordon
D001024:Aortic Valve Stenosis / Q000601:surgery*; D006350:Heart Valve Prosthesis; D006801:Humans; D011474:Prosthesis Design; D065467:Transcatheter Aortic Valve Replacement; D016896:Treatment Outcome
Aortic Stenosis; Transcather Aortic Valve Replacement